摘要
目的:系统评价利伐沙班在预防静脉血栓栓塞的经济学特性。方法:系统检索Pubmed、Embase、Cochrane library、 CNKI、万方、 CBM等数据库,搜集关于利伐沙班防治VTE的药物经济学研究,检索时间从建库截至2017年8月。结果:共纳入13篇文献,均为药物经济学研究,研究对象为进行抗凝治疗或预防的VTE患者。10篇文献的对照措施为传统抗凝药依诺肝素或华法林,其中9篇报道显示,利伐沙班具有成本-效果优势,增量-成本-效果比(ICER)在各国的可接受的意愿支付阈值之内。2篇文献分别显示,在预防和治疗复发性静脉血栓栓塞或急性静脉血栓栓塞时,阿哌沙班或达比加群的经济性均优于利伐沙班。结论:现有证据表明,利伐沙班在VTE的预防和治疗中,较传统抗凝治疗(依诺肝素或华法林)具有良好的经济学优势,但与其他新型口服抗凝药相比,其是否具有经济性还需更多的临床数据和文献的支持。
Objective To systematically evaluate the economics of rivaroxaban for anticoagulation treatment or prevention in venous thromboembolism （VTE）.MethodsPubmed,Embase,Cochrane library,CNKI,Wanfang data and CBM were systematically searched to collect pharmacoeconomics study about rivaroxaban for VTE treatment or prevention from inception to Aug 2017.ResultsThe search identified 13 pharmacoeconomics studies.The patients included were for anticoagulation treatment in VTE.Compared with enoxaparin and warfarin,nine of 10 reports displayed rivaroxaban were cost-effectiveness,ICER within willing-to-pay threshold.Two studies disclosure that rivaroxaban cost more than dabigatran and apixaban in treatment and prevention of VTE .ConclusionThe current evidence showed that,rivaroxaban is cost-effectiveness for treatment or prevention of VTE compared with traditional anticoagulation treatment such as enoxaparin and warfarin.It still needs more high quality clinical studies to verify the economics of rivaroxaban and other new oral anticoagulants.
作者
李超
李娜
董淑杰
封宇飞
LI Chao;LI Na;DONG Shu-jie;FENG Yu-fei(Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Beijing 100730,China;Department of Pharmacy,Fujian Medical University Union Hospital,Fuzhou 350001,China;Department of Pharmacy,Peking University Third Hospital,Beijing 100191,China)
出处
《临床药物治疗杂志》
2018年第10期21-25,共5页
Clinical Medication Journal
关键词
静脉血栓栓塞
利伐沙班
药物经济学
系统评价
venous thromboembolism （VTE）
rivaroxaban
pharmacoeconomics
systematic review
